NICE

MIB120 Caris Molecular Intelligence for guiding cancer treatment

Caris Molecular Intelligence (CMI) is used to help guide future management of locally advanced or metastatic cancer. Its intended place in therapy would be as a tool to help guide treatment decisions for locally advanced or metastatic cancer in people who are fit for further treatment but have exhausted standard (evidence-based) treatment options and for whom no further guidance on therapy exists.

NICE page: https://www.nice.org.uk/advice/mib120